Optimum management of type 2 diabetes – timely introduction, optimization and intensification of basal insulin
- 10 June 2008
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (s2), 5-13
- https://doi.org/10.1111/j.1463-1326.2008.00840.x
Abstract
The natural progression of type 2 diabetes mellitus (T2DM) requires continuing medical care, early insulin intensification and patient self-management education to reduce the risk of long-term complications, including microvascular and macrovascular complications. However, too few people are on insulin, and all too commonly have poor glycaemic control. This paradigm significantly increases the risk for long-term complications. It is becoming increasingly apparent that the early introduction of basal insulin, such as insulin glargine, is essential to provide clinically important improvements in glycaemic control. In this review, we discuss the rationale for the earlier insulinization in T2DM in order to reach and maintain treatment targets and to provide further support for the recent American Diabetes Association and European Association for the Study of Diabetes consensus statement.Keywords
This publication has 60 references indexed in Scilit:
- Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2008
- The cost‐effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economicsDiabetes, Obesity and Metabolism, 2008
- Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experienceDiabetes, Obesity and Metabolism, 2008
- Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trialThe Lancet, 2008
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Insulin detemir under steady‐state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetesDiabetic Medicine, 2006
- A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 DiabetesHormone and Metabolic Research, 2003
- When oral agents fail: practical barriers to starting insulinInternational Journal of Obesity, 2002
- Global and societal implications of the diabetes epidemicNature, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998